Comparing cDC1 vs cDC2: Key Features and Roles in Immunology

Conventional dendritic cells come in two major flavors, cDC1 and cDC2, and their central difference boils down to which arm of the immune response each one orchestrates. cDC1s specialize in cross-presenting antigen to CD8+ killer T cells, while cDC2s primarily activate CD4+ helper T cells and steer them toward different inflammatory profiles. That functional split has enormous consequences for how the body fights cancer, clears infections, and sometimes causes allergic disease, making the cDC1/cDC2 distinction one of the most consequential in modern immunology.

How cDC1 and cDC2 Develop From Shared Progenitors

Both cDC1s and cDC2s trace their origins to bone marrow progenitors that share a common feature: surface expression of the Flt3 receptor, also called CD135.¹ The growth factor that binds this receptor, Flt3 ligand (FLT3L), is the master signal that drives dendritic cell production. From there, the two subsets diverge under the control of different transcription factors. cDC1 development depends on high levels of the transcription factor IRF8, while cDC2 differentiation relies on its relative, IRF4.² Think of IRF8 and IRF4 as competing switches: the progenitor cell that cranks up IRF8 commits to becoming a cDC1, while one that leans toward IRF4 heads down the cDC2 path.

The machinery behind IRF8 induction in cDC1 progenitors has been mapped in detail. A cascade of transcription factors, including RUNX proteins acting upstream of C/EBPα, activates a specific regulatory region called the +56-kilobase enhancer of the Irf8 gene. Mutations at that enhancer dramatically reduce IRF8 levels in myeloid progenitors and cripple cDC1 development.³ This elaborate chain of regulatory interactions helps explain why cDC1s are relatively rare cells; generating them requires multiple transcriptional checkpoints to be passed in precisely the right order.

The Core Functional Split

The feature that defines cDC1s more than anything else is cross-presentation, the ability to take up material from dead or infected cells and load those protein fragments onto the molecular machinery (MHC class I) that alerts CD8+ cytotoxic T cells. This is not a trivial task. Most cells only present their own internal proteins on MHC class I. cDC1s have evolved specialized pathways that allow externally acquired antigens to access that same route, effectively telling CD8+ T cells about threats the cDC1 encountered outside itself.⁴

How exactly cross-presentation works is still debated. Two models compete. In the vacuolar pathway, antigens stay inside membrane-bound compartments and get loaded onto MHC class I without ever entering the cell’s main cytoplasm. In the cytosolic pathway, phagosomes rupture and dump antigens into the cytoplasm, where they undergo proteasomal degradation before loading. Recent work points to a protein called WDFY4 as strictly required for cross-presentation of cell-associated antigens in living animals, regardless of which route dominates.⁵ A receptor called CLEC9A on cDC1s can trigger phagosomal rupture through SYK kinase signaling, feeding into the cytosolic route, but the vacuolar route likely operates in parallel.

cDC2s, by contrast, excel at presenting antigen on MHC class II to CD4+ helper T cells. Rather than funneling external proteins into the CD8+ T cell alert system, cDC2s process them through the conventional endosomal pathway and activate the helper side of adaptive immunity. This makes cDC2s the primary drivers of antibody responses, allergic inflammation, and several flavors of helper T cell polarization.

Driving Different T Cell Responses

The distinction between cDC1 and cDC2 is not just about which T cell class they talk to. Each subset steers the T cells it activates toward particular inflammatory programs. cDC1s are potent inducers of Th1 responses, the pro-inflammatory programs centered on interferon-gamma that are critical for clearing intracellular pathogens and killing tumor cells. Experiments using bone marrow-derived dendritic cell vaccines showed that endogenous cDC1s (specifically XCR1+CD103+ cells) were the indispensable “bystander” subset that provided the third signal required for full Th1 polarization, even when the initial vaccination was done with a different DC population.⁶ Without host cDC1s present, the injected vaccine DCs could not drive a proper Th1 response on their own.

cDC2s are more versatile in their T helper cell programming. Depending on the context, they can promote Th2 responses (the kind involved in allergic disease and parasite defense), Th17 responses (important for mucosal barrier protection and autoimmunity), or even regulatory T cell induction. Lung studies revealed that a subset of cDC2s marked by Ly-6C strongly promoted Th17 differentiation, while cDC1s had only weak activity in that regard.⁷ In the lungs specifically, a TNFR2+ cDC2 population was found to maintain tolerance at baseline by inducing regulatory T cells, but switched to promoting Th2 responses during house dust mite-driven asthma.⁸ That dual personality makes cDC2s central players in both protective immunity and allergic pathology.

cDC2 Is Not One Thing

One of the bigger shifts in the field over the past few years is the recognition that “cDC2” is actually an umbrella term covering at least two developmentally distinct subsets, now called cDC2A and cDC2B. This is not just a matter of surface marker gradients or tissue-driven plasticity. Work tracking progenitor cells in mouse bone marrow showed that different precursors have a differential propensity to generate cDC2As versus cDC2Bs, and that this specification begins in the bone marrow before the cells ever reach peripheral tissues.⁹ The implication is that cDC1, cDC2A, and cDC2B are each genuine lineages, prespecified before deployment, rather than flexible states shaped by the local environment.

Adding further complexity, cDC2 progenitors can arrive through both myeloid and lymphoid developmental routes. A bone marrow progenitor population called “pro-cDC2” encompasses myeloid-derived pre-cDC2 cells and lymphoid-derived plasmacytoid-DC-like precursors, both of which converge on a shared cDC2 phenotype despite their different origins.¹⁰ These routes have distinct transcription factor requirements: the myeloid path depends more heavily on KLF4, while the lymphoid path does not.¹⁰ The cDC2A/cDC2B distinction and the dual ontogeny together mean that what researchers once called “the cDC2 compartment” is a mosaic, and its diversity has real functional consequences for tissue-specific immune responses.¹¹

Why cDC1s Matter So Much in Cancer

If there is one area where the cDC1/cDC2 distinction has landed with real clinical force, it is tumor immunology. cDC1s are the primary bridge between a tumor and the CD8+ killer T cells that can destroy it. They take up tumor-derived material, cross-present tumor antigens, and migrate to draining lymph nodes where they prime cancer-specific cytotoxic T lymphocytes. In patient data, higher cDC1 density within tumors has been associated with better survival.¹² In mouse models, removing cDC1s abolishes the spontaneous rejection of immunogenic cancers and eliminates the benefit of checkpoint inhibitor therapy.⁴

That last point is worth pausing on. Checkpoint inhibitors like anti-PD-1 antibodies have transformed cancer treatment, but they only work in a fraction of patients. A growing body of evidence suggests that one reason for non-response is insufficient cDC1 infiltration in the tumor. Without enough cDC1s to present tumor antigens and kick-start CD8+ T cell responses, releasing the brakes on T cells with a checkpoint inhibitor does little. Preclinical strategies are now being tested to solve this problem by boosting cDC1 numbers directly at the tumor site. One approach used cDC1 cells engineered to secrete FLT3L as an in situ vaccine; combined with anti-PD-1 therapy, this led to complete tumor regression in roughly 85% of treated mice with non-small cell lung cancer models.¹³

How They Sense Pathogens Differently

cDC1s and cDC2s do not detect microbial threats in identical ways. Their expression profiles of Toll-like receptors and their downstream signaling responses differ, which shapes the kind of immune alarm each subset sounds. In a porcine model of respiratory virus infection, cDC1s expressed higher levels of interferon-alpha while cDC2s produced more of the immunosuppressive cytokine IL-10. The cDC2 subset also showed greater upregulation of TLR2 and TLR4, surface receptors that detect bacterial components, while a subset of CD163+ cells upregulated TLR3, which senses double-stranded RNA.¹⁴

In humans, transcriptomic analysis after TLR7 activation (TLR7 being a sensor for single-stranded RNA viruses) showed that both cDC1 and cDC2 mounted interferon-related transcriptional programs, but with meaningful differences in scale. cDC2 cells showed strong, consistent induction of canonical interferon-response genes like ISG15, MX1, IFIT1, STAT1, and IRF7. cDC1 cells, by comparison, displayed more heterogeneous changes in those same interferon-associated transcripts.¹⁵ This does not mean cDC1s are passive during viral infections. Their strength lies more in producing IL-12 and activating CD8+ T cells than in the interferon amplification loop that cDC2s handle so robustly.

The cDC2 and Monocyte-Derived DC Identity Problem

One of the persistent headaches in dendritic cell biology is telling cDC2s apart from monocyte-derived dendritic cells (MoDCs). During inflammation, monocytes from the blood can differentiate into cells that look and act a lot like cDC2s, expressing overlapping surface markers including CD11b, CD11c, SIRPα, and MHC class II.¹⁶ In inflamed tissue, proper phenotypical discrimination between the two remains genuinely challenging, and this has muddied the interpretation of many studies that report “cDC2” findings without adequately excluding contaminating MoDCs.

This is not just an academic bookkeeping issue. cDC2s and MoDCs have different developmental origins, respond to different growth factors, and likely play distinct roles in disease. Studies that lump them together risk misattributing a function to one cell type when the other was actually responsible. The field has been working on marker panels and transcriptomic signatures that can cleanly separate the two populations, but a universally accepted protocol remains elusive, especially in human tissues. Researchers reading claims about “cDC2 function” during inflammation should always ask whether the study adequately excluded monocyte-derived cells from the analysis.

Therapeutic Strategies Targeting Each Subset

The distinct biology of cDC1 and cDC2 has opened two different therapeutic playbooks. For cDC1s, the goal in cancer immunotherapy is usually to boost their numbers and activity inside tumors. One promising approach exploits the chemokine receptor XCR1, which is selectively expressed by cross-presenting dendritic cells. By engineering antigen-delivery vehicles that bind XCR1, researchers can route tumor antigens specifically to cDC1s, enhancing the CD8+ T cell response without broadly activating all immune cells.¹⁷

But cDC1 targeting is not always about amplification. In atherosclerosis, cDC1s appear to promote harmful local inflammation within arterial plaques. Researchers generated lipid nanoparticles decorated with an antibody against CLEC9A (the same receptor involved in cross-presentation) to specifically deliver the immunosuppressive drug dexamethasone to cDC1s. In mice, these targeted nanoparticles shrank atherosclerotic lesions and reduced inflammatory T cell populations without impairing the animals’ ability to fight viral infections.¹⁸ The fact that the same cell type needs boosting in one disease context and suppression in another neatly illustrates why blanket immune modulation is such a blunt instrument compared with subset-targeted approaches.

For cDC2-directed therapies, the interest often centers on allergic and autoimmune conditions. Because cDC2s drive Th2 and Th17 polarization, intervening at the cDC2 level could potentially reprogram allergic inflammation upstream of the T cell response. The study showing that interferon-beta could reprogram pathogenic lung TNFR2+ cDC2s away from Th2 promotion in a mouse asthma model illustrates the concept.⁸ Rather than targeting the downstream T cells or blocking individual cytokines, reprogramming the dendritic cell that initiates the cascade could offer more durable control.

How Aging Reshapes the cDC1/cDC2 Balance

Aging does not treat cDC1 and cDC2 equally. In humans, the circulating percentages of both subsets decline with age, but cDC2s also show a measurable drop in phagocytic capacity, meaning not only are there fewer of them, the survivors work less efficiently.¹⁹ In mouse bone marrow, aging selectively reduces myeloid-derived dendritic cell precursors while leaving lymphoid-derived plasmacytoid DC precursors relatively intact. Within the conventional DC branch, cDC2-committed precursors appear particularly vulnerable, showing significant reductions in aged animals.²⁰

The functional consequences go beyond raw cell counts. Key antiviral signaling proteins, specifically phosphorylated IRF7 and phosphorylated TBK-1, are reduced in both cDC1s and cDC2s from older adults compared to younger individuals. That decrease correlates with impaired phagocytosis, suggesting that the cells are not just fewer but also molecularly hobbled in their pathogen-detection circuitry.²¹ These findings offer one mechanistic explanation for why older adults respond poorly to viral infections and vaccines: the dendritic cells that should be initiating the immune response are both depleted and functionally impaired, and the deficit hits both branches of conventional DC biology.

For vaccine design, this has practical implications. If older adults have fewer cDC1s and those cDC1s have dampened antiviral signaling, strategies that rely on cDC1-mediated cross-presentation to generate CD8+ T cell responses may underperform in the population that needs them most. Adjuvants or delivery systems specifically designed to compensate for age-related DC deficits, perhaps by targeting surviving cDC1s more efficiently or by using FLT3L to expand progenitors, are an active area of investigation. The age-related vulnerability of cDC2-committed precursors also suggests that Th17 and Th2 immunity, both downstream of cDC2 function, may be disproportionately affected in the elderly, with consequences for mucosal defense and barrier integrity.